Gene · 10643
IGF2BP3: insulin like growth factor 2 mRNA binding protein 3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. IGF2BP3: insulin like growth factor 2 mRNA binding protein 3. Genes, record 10643. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10643
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O00425 | Insulin-like growth factor 2 mRNA-binding protein 3 | 579 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents88
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 49921 | O00425 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 1310 | O00425 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4495 | O00425 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 1310 | O00425 | Espacenet |
| KR 1020250036258 A | 2025-03-13 | 32 | O00425 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4495 | O00425 | Espacenet |
| EP 4487869 A2 | 2025-01-08 | 231 | O00425 | Espacenet |
| US 12023371 B2 | 2024-07-02 | 4652 | O00425 | Espacenet |
| EP 4353321 A2 | 2024-04-17 | 110 | O00425 | Espacenet |
| KR 1020240027895 A | 2024-03-04 | 423 | O00425 | Espacenet |
1 to 10 of 88
See all 88 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants947
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | IGF2BP3 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016042 | Cancer Center Support Grant | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| T32CA009056 | Tumor Cell Biology Training Program | 5 | 2025 |
| P50AA011999 | Southern California Research Center for ALPD and Cirrhosis | 4 | 2025 |
| R01CA264986 | Protein-RNA interactions in cancer | 4 | 2025 |
| R24AA012885 | Integrative Liver Cell Core | 4 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 3 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 3 | 2025 |
| P30CA023074 | University of Arizona Cancer Center - Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 947Source NIH's project files
See all 947 nih grantsPapers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| IGF2BP3 promotes esophageal squamous cell carcinoma progression by regulating global protein translation. | Biochim Biophys Acta Mol Basis Dis | 2027 | 42603622 | PubTator, text mining | PubMed |
| IGF2BP3 remodels RISC occupancy to control microRNA targeting in leukemia. | NAR Cancer | 2026 | 42780509 | PubTator, text mining | PubMed |
| A Metabolic-Epigenetic Axis of AARS1/IGF2BP3-K280 Lactylation Sustains Endometrial Cancer Stemness and Recurrence. | Adv Sci (Weinh) | 2026 | 42775431 | PubTator, text mining | PubMed |
| IGF2BP3 drives macrophage M1 polarization to promote intracranial aneurysm rupture through m6A-mediated NPY1R stabilization. | Peptides | 2026 | 42772570 | PubTator, text mining | PubMed |
| Programmed ribosomal frameshifting triggers translational stress to promote viral replication. | Cell | 2026 | 42743925 | PubTator, text mining | PubMed |
| Development of m6A-related prognostic models for survival in lung squamous cell carcinoma with different PD-L1 expression levels. | Transl Cancer Res | 2026 | 42724890 | PubTator, text mining | PubMed |
| IGF2BP3 enhances paclitaxel resistance in bladder urothelial carcinoma by recognizing m6A-modified CENPA mRNA. | Med Oncol | 2026 | 42720822 | PubTator, text mining | PubMed |
| Correction to "IGF2BP3-Dependent N6-Methyladenosine Modification of USP49 Promotes Carboplatin Resistance in Retinoblastoma by Enhancing Autophagy via Regulating the Stabilization of SIRT1". | Kaohsiung J Med Sci | 2026 | 42717291 | PubTator, text mining | PubMed |
| WTAP-mediated m6A modification upregulates the circCDK8 to promote ferroptosis in periodontal ligament stem cells. | Biochem Pharmacol | 2026 | 42679908 | PubTator, text mining | PubMed |
| Role and prognostic value of N6-methyladenosine RNA modification regulators in glycolytic reprogramming during sepsis. | J Intensive Care | 2026 | 42675521 | PubTator, text mining | PubMed |
1 to 10 of 3,038
See all 3,038 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/10643
GET https://conductscience.org/api/genes/v1/10643/patents?page=2